References
- Diamond A, Jankovic J. Treatment of advanced Parkinson’s disease. Expert Rev Neurother 2006;6:1181-97
- Perez-Lloret SS, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs 2010;24:941-68
- Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson’s disease. Drugs 2000;60:115-37
- Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 1996;19:234-45
- Prescribing information: ReQuip XL extended-release tablets. 2012. Available at: www.us.gsk.com/products/assets/us_requip.pdf [Last accessed Aug 2012]
- Patient Information Leaflet: ReQuip XL prolonged-release tablets. 2012. Available at: www.medicines.org.uk/emc/medicine/200882 [Last accessed Aug 2012]
- A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson’s Disease Who Are Not Optimally Controlled on L-Dopa. NCT01154166. Available at: www.ClinicalTrials.gov [Last accessed Aug 2012]
- Zhang Z, Wang J, Zhang X, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: A multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism and Related Disorders 2013;19(11):1022-6
- Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology 2001;57(10 Suppl 3):S11-26
- Kim SW, Grant JE, Potenza MN, et al. The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res 2009;166:76-84
- Pahwa R, Stacy MA, Factor SA, et al. EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in Parkinson disease. Neurology 2007;68:1108-15
- Stocchi F, Hersh BP, Scott BL, et al. Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008;24:2883-95
- Hauser RA, Reichmann H, Lew M, et al. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson’s disease. Int J Neuroscience 2011;121:246-53
- Kulisevsky JJ. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinsons disease: meta-analysis of randomized controlled trials. Drug Saf 2010;33:147-61
- Clinical and research information on drug-induced liver injury: ropinirole. National Library of Medicine, USA. Last updated 18 July 2013. Available at: www.livertox.nlm.nih.gov/ropinirole.htm [Last accessed 20 September 2013]